Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REPLIGEN CORPRGEN · Entity 486 | Director | May 14, 2026 | May 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REPLIGEN CORP
Report date May 14, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,011 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 995 · Balance 3,011 F1: Ms. Pax was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $103.38 · Expires 2036-05-14 | Direct | 2,239 |
Reported balance
After 2026-05-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-14 · Grant · Acquired 2,239 · Balance 2,239 F2: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. |
Filing footnotes · ownership attribution and instrument terms
F1: Ms. Pax was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
F2: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALIMERA SCIENCES INC
Report date September 16, 2024 · Filed September 18, 2024
Section 16 reporting ended · disclosed 2024-09-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.42 · Expires 2033-11-06 | Direct | 0 |
Reported balance
After 2024-09-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-09-16 · Disposition to issuer · Disposed 36,713 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of June 21, 2024 (the "Merger Agreement"), by and among the Issuer, ANI Pharmaceuticals, Inc., a Delaware corporation ("Parent") and ANIP Merger Sub INC., a Delaware corporation and a wholly owned indirect subsidiary of Parent, as of the effective time of the merger (the "Effective Time"), at the Effective Time, each stock option granted by the Issuer to purchase shares (each, an "Option") that was outstanding and unvested immediately prior to the Effective Time vested in full, and each Option that was outstanding and unexercised which had a per share exercise price that was less than ) $5.50 in cash, without interest (such amount, the "Closing Cash Consideration") was converted into the right to receive the sum of an amount in cash (without interest and subject to deduction for any required withholding as contemplated in the Merger Agreement) equal to: F2: (A) the excess, if any, of the Closing Cash Consideration over the exercise price per share of such Option; multiplied by the number of shares underlying such Option and (B) one contingent value right ("CVR") representing the right to receive contingent cash payments subject to the achievement of certain milestones and the terms and conditions set forth in a contingent value rights agreement entered into between Parent and a rights agent. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of June 21, 2024 (the "Merger Agreement"), by and among the Issuer, ANI Pharmaceuticals, Inc., a Delaware corporation ("Parent") and ANIP Merger Sub INC., a Delaware corporation and a wholly owned indirect subsidiary of Parent, as of the effective time of the merger (the "Effective Time"), at the Effective Time, each stock option granted by the Issuer to purchase shares (each, an "Option") that was outstanding and unvested immediately prior to the Effective Time vested in full, and each Option that was outstanding and unexercised which had a per share exercise price that was less than ) $5.50 in cash, without interest (such amount, the "Closing Cash Consideration") was converted into the right to receive the sum of an amount in cash (without interest and subject to deduction for any required withholding as contemplated in the Merger Agreement) equal to:
F2: (A) the excess, if any, of the Closing Cash Consideration over the exercise price per share of such Option; multiplied by the number of shares underlying such Option and (B) one contingent value right ("CVR") representing the right to receive contingent cash payments subject to the achievement of certain milestones and the terms and conditions set forth in a contingent value rights agreement entered into between Parent and a rights agent.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 14, 2026 Filed May 18, 2026 20:05 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 2,239 | $0.00 Strike: $103.38 | $0.00 |
DisclosureSEC source: 0001193125-26-228886 · ownership.xml · derivative · entry 2 Pax Margaret · CIK 0001999772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,239 Underlying: Common Stock · 2,239 shares Expires 2036-05-14 F2 · derivative.exercise_date: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:05 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 995 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-228886 · ownership.xml · nonDerivative · entry 1 Pax Margaret · CIK 0001999772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,011 F1 · shares: Ms. Pax was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| May 15, 2025 Filed May 19, 2025 18:59 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 1,800 | $0.00 Strike: $123.26 | $0.00 |
DisclosureSEC source: 0000950170-25-074216 · ownership.xml · derivative · entry 2 Pax Margaret · CIK 0001999772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,800 Underlying: Common Stock · 1,800 shares Expires 2035-05-15 F2 · derivative.exercise_date: Award vests in full on the earlier of May 15, 2026, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document |
| May 15, 2025 Filed May 19, 2025 18:59 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 973 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-074216 · ownership.xml · nonDerivative · entry 1 Pax Margaret · CIK 0001999772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,016 F1 · shares: Ms. Pax was awarded 973 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 15, 2026, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 19:58 UTC | REPLIGEN CORP RGEN · Entity 486 | PurchaseCommon Stock | 250 | $150.69 | $37,672.50 |
DisclosureSEC source: 0000950170-25-041119 · ownership.xml · nonDerivative · entry 1 Pax Margaret · CIK 0001999772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,043 Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 21:53 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | Disposition to issuerStock Option (Right to Buy) · Derivative | 36,713 | Not disclosed Strike: $3.42 | Not disclosed |
DisclosureSEC source: 0001104659-24-101111 · tm2424353-8_4seq1.xml · derivative · entry 1 Pax Margaret · CIK 0001999772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,713 shares Expires 2033-11-06 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of June 21, 2024 (the "Merger Agreement"), by and among the Issuer, ANI Pharmaceuticals, Inc., a Delaware corporation ("Parent") and ANIP Merger Sub INC., a Delaware corporation and a wholly owned indirect subsidiary of Parent, as of the effective time of the merger (the "Effective Time"), at the Effective Time, each stock option granted by the Issuer to purchase shares (each, an "Option") that was outstanding and unvested immediately prior to the Effective Time vested in full, and each Option that was outstanding and unexercised which had a per share exercise price that was less than ) $5.50 in cash, without interest (such amount, the "Closing Cash Consideration") was converted into the right to receive the sum of an amount in cash (without interest and subject to deduction for any required withholding as contemplated in the Merger Agreement) equal to: F2 · price: (A) the excess, if any, of the Closing Cash Consideration over the exercise price per share of such Option; multiplied by the number of shares underlying such Option and (B) one contingent value right ("CVR") representing the right to receive contingent cash payments subject to the achievement of certain milestones and the terms and conditions set forth in a contingent value rights agreement entered into between Parent and a rights agent. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of June 21, 2024 (the "Merger Agreement"), by and among the Issuer, ANI Pharmaceuticals, Inc., a Delaware corporation ("Parent") and ANIP Merger Sub INC., a Delaware corporation and a wholly owned indirect subsidiary of Parent, as of the effective time of the merger (the "Effective Time"), at the Effective Time, each stock option granted by the Issuer to purchase shares (each, an "Option") that was outstanding and unvested immediately prior to the Effective Time vested in full, and each Option that was outstanding and unexercised which had a per share exercise price that was less than ) $5.50 in cash, without interest (such amount, the "Closing Cash Consideration") was converted into the right to receive the sum of an amount in cash (without interest and subject to deduction for any required withholding as contemplated in the Merger Agreement) equal to: F2 · derivative.exercise_date: (A) the excess, if any, of the Closing Cash Consideration over the exercise price per share of such Option; multiplied by the number of shares underlying such Option and (B) one contingent value right ("CVR") representing the right to receive contingent cash payments subject to the achievement of certain milestones and the terms and conditions set forth in a contingent value rights agreement entered into between Parent and a rights agent. Read SEC document |
| May 16, 2024 Filed May 20, 2024 23:30 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 1,376 | $0.00 Strike: $171.03 | $0.00 |
DisclosureSEC source: 0000950170-24-062616 · ownership.xml · derivative · entry 2 Pax Margaret · CIK 0001999772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,376 Underlying: Common Stock · 1,376 shares Expires 2034-05-16 F2 · derivative.exercise_date: Award vests in full on the earlier of May 16, 2025, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document |
| May 16, 2024 Filed May 20, 2024 23:30 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 701 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062616 · ownership.xml · nonDerivative · entry 1 Pax Margaret · CIK 0001999772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 793 F1 · shares: Ms. Pax was awarded 701 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 16, 2025, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| March 18, 2024 Filed Mar 19, 2024 22:19 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 2,236 | $0.00 Strike: $194.25 | $0.00 |
DisclosureSEC source: 0000950170-24-033756 · ownership.xml · derivative · entry 3 Pax Margaret · CIK 0001999772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,236 Underlying: Common Stock · 2,236 shares Expires 2034-03-18 F3 · derivative.exercise_date: The shares vest in equal annual instalments over a three-year period with each such vesting date occurring on the earlier of the anniversary of the grant date or the date of the annual meeting of the Company's shareholders of the applicable year of such three-year period. Read SEC document |
| March 18, 2024 Filed Mar 19, 2024 22:19 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 195 | $0.00 Strike: $194.25 | $0.00 |
DisclosureSEC source: 0000950170-24-033756 · ownership.xml · derivative · entry 2 Pax Margaret · CIK 0001999772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195 Underlying: Common Stock · 195 shares Expires 2034-03-18 F2 · derivative.exercise_date: Award vests in full on May 16, 2024, the date of the annual meeting of the Company's shareholders. Read SEC document |
| March 18, 2024 Filed Mar 19, 2024 22:19 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 92 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-033756 · ownership.xml · nonDerivative · entry 1 Pax Margaret · CIK 0001999772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92 F1 · shares: Ms. Pax was awarded 92 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on May 16, 2024, the date of the annual meeting of the Company's shareholders. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| November 07, 2023 Filed Nov 8, 2023 18:58 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | GrantStock Option (Right to Buy) · Derivative | 36,713 | $0.00 Strike: $3.42 | $0.00 |
DisclosureSEC source: 0000950170-23-061355 · ownership.xml · derivative · entry 1 Pax Margaret · CIK 0001999772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,713 Underlying: Common Stock · 36,713 shares Expires 2033-11-06 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments beginning on November 7, 2023. Vests in full on the earlier of August 1, 2024 or the date of the Issuer's 2024 annual meeting of stockholders, provided the Reporting Person provides continuous service to the Issuer through such date, with the final installment adjusted as necessary to avoid any fractional shares in any installment. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.